ERBB2 and neoplasm: These results demonstrate that the antitumor efficacy of AST1306 is greater in ErbB2-overexpressing tumor models than in models expressing low levels of ErbB2, consistent with the results of in vitro proliferation experiments and siRNA-mediated inhibition assays.